Literature DB >> 3334817

Anaplastic thyroid carcinoma. Association with differentiated thyroid cancer.

J R Spires1, M R Schwartz, R H Miller.   

Abstract

Fourteen cases of anaplastic thyroid carcinoma (ATC) treated at Baylor College of Medicine, Houston, during a 19-year period were reviewed. There was a 1.3:1 female preponderance, and the median patient age was 62 years. Ten (71%) of the anaplastic tumors either followed or occurred simultaneously with a well-differentiated thyroid carcinoma. This finding adds support to the theory that ATC usually results from the transformation of well-differentiated thyroid carcinoma. A combination of surgery, radiation therapy, and chemotherapy was utilized for most patients. In this series of patients, the median duration of survival was four months following diagnosis, with only three patients (21%) alive at one year. Despite aggressive therapy, the prognosis for ATC remains poor.

Entities:  

Mesh:

Year:  1988        PMID: 3334817     DOI: 10.1001/archotol.1988.01860130044012

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  21 in total

Review 1.  Anaplastic thyroid carcinoma.

Authors:  P I Haigh
Journal:  Curr Treat Options Oncol       Date:  2000-10

2.  MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas.

Authors:  Kepal N Patel; Ellie Maghami; Volkert B Wreesmann; Ashok R Shaha; Jatin P Shah; Ronald Ghossein; Bhuvanesh Singh
Journal:  Surgery       Date:  2005-12       Impact factor: 3.982

Review 3.  Alterations of the BRAF gene in thyroid tumors.

Authors:  Raffaele Ciampi; Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

4.  Genome-wide appraisal of thyroid cancer progression.

Authors:  Volkert B Wreesmann; Ronald A Ghossein; Snehal G Patel; Charles P Harris; Erik A Schnaser; Ashok R Shaha; R Michael Tuttle; Jatin P Shah; Pulivarthi H Rao; Bhuvanesh Singh
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

5.  Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.

Authors:  Alyaksandr V Nikitski; Susan L Rominski; Vincenzo Condello; Cihan Kaya; Mamta Wankhede; Federica Panebianco; Hong Yang; Daniel L Altschuler; Yuri E Nikiforov
Journal:  Thyroid       Date:  2019-08-16       Impact factor: 6.568

6.  Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.

Authors:  Francesco Perri; Giuseppe Di Lorenzo; Giuseppina Della Vittoria Scarpati; Carlo Buonerba
Journal:  World J Clin Oncol       Date:  2011-03-10

7.  Coexisting well-differentiated and anaplastic thyroid carcinoma in the same primary resection specimen: immunophenotypic and genetic comparison of the two components in a consecutive series of 13 cases and a review of the literature.

Authors:  Moira Ragazzi; Federica Torricelli; Benedetta Donati; Alessia Ciarrocchi; Dario de Biase; Giovanni Tallini; Eleonora Zanetti; Alessandra Bisagni; Elisabetta Kuhn; Davide Giordano; Andrea Frasoldati; Simonetta Piana
Journal:  Virchows Arch       Date:  2020-07-18       Impact factor: 4.064

8.  Molecular therapeutics for anaplastic thyroid cancer.

Authors:  Nikita Pozdeyev; Madison M Rose; Daniel W Bowles; Rebecca E Schweppe
Journal:  Semin Cancer Biol       Date:  2020-01-25       Impact factor: 15.707

9.  Warthin tumor-like papillary thyroid carcinoma with a minor dedifferentiated component: report of a case with clinicopathologic considerations.

Authors:  Paolo Amico; Salvatore Lanzafame; Giovanni Li Destri; Paolo Greco; Rosario Caltabiano; Giada Maria Vecchio; Gaetano Magro
Journal:  Case Rep Med       Date:  2010-06-07

10.  PDCD4 expression in thyroid neoplasia.

Authors:  Gianmaria Pennelli; Matteo Fassan; Caterina Mian; Marco Pizzi; Mariangela Balistreri; Susi Barollo; Francesca Galuppini; Vincenza Guzzardo; Mariarosa Pelizzo; Massimo Rugge
Journal:  Virchows Arch       Date:  2012-12-05       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.